Bobak R. Azamian net worth and biography

Bobak Azamian Biography and Net Worth

Bobby has served as President and CEO of Tarsus Pharmaceuticals since co-founding the company in 2017. In that time, Tarsus has established a leading team and culture, and completed successful fundraising efforts through an IPO and global partnerships. Tarsus continues to advance its pipeline into clinical studies, including its lead product, TP-03, which is now in Phase 3 clinical trials and commercial planning.

Bobby also serves on the board and is Co-Chairman of Vibrato Medical, a medical device company developing a wearable treatment for peripheral arterial diseases, which has received NIH grant awards and generated first-in-human proof of concept clinical data. Previously, he was President and CMO of Metavention, a medical device company developing an interventional treatment for metabolic diseases, from inception through proof of concept clinical trials as well as Series A through Series C fundraising.

Bobby began his biotechnology career at Versant Ventures and Third Rock Ventures, where he was an investor and board observer in numerous life sciences companies. He also served on the board of the nonprofit organization Octane.

He trained as a physician scientist, completing his residency in internal medicine and serving as an attending hospitalist at Brigham and Women’s Hospital. He received an MD from Harvard Medical School (Harvard-MIT Heath Sciences and Technology), a PhD in chemistry from Oxford University as a Rhodes Scholar, and a BA in physics from Rice University. He is also an author of numerous patents and peer-reviewed publications.

What is Bobak R. Azamian's net worth?: The estimated net worth of Bobak R. Azamian is at least $2.74 million as of March 20th, 2025. Dr. Azamian owns 53,635 shares of Tarsus Pharmaceuticals stock worth more than $2,735,921 as of March 26th. This net worth estimate does not reflect any other assets that Dr. Azamian may own. Learn More about Bobak R. Azamian's net worth.
How do I contact Bobak R. Azamian?: The corporate mailing address for Dr. Azamian and other Tarsus Pharmaceuticals executives is , , . Tarsus Pharmaceuticals can also be reached via phone at 949-409-9820 and via email at ir@tarsusrx.com. Learn More on Bobak R. Azamian's contact information.
Has Bobak R. Azamian been buying or selling shares of Tarsus Pharmaceuticals?: Within the last three months, Bobak R. Azamian has sold $757,732.73 in shares of Tarsus Pharmaceuticals stock. Most recently, Bobak R. Azamian sold 8,534 shares of the business's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $50.11, for a transaction totalling $427,638.74. Following the completion of the sale, the chief executive officer now directly owns 53,635 shares of the company's stock, valued at $2,687,649.85. Learn More on Bobak R. Azamian's trading history.
Who are Tarsus Pharmaceuticals' active insiders?: Tarsus Pharmaceuticals' insider roster includes D. Ackermann (Director), Bobak Azamian (CEO), Andrew Goldberg (Director), Leonard Greenstein (CFO), Elizabeth Lin (Director), Aziz Mottiwala (Insider), Seshadri Neervannan (COO), Bryan Wahl (General Counsel), and Dianne Whitfield (Chief Human Resources Officer). Learn More on Tarsus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Tarsus Pharmaceuticals?: During the last year, insiders at the sold shares 6 times. They sold a total of 26,542 shares worth more than $1,281,173.28. The most recent insider tranaction occured on March, 20th when General Counsel Bryan Wahl sold 3,084 shares worth more than $154,539.24. Insiders at Tarsus Pharmaceuticals own 8.3% of the company. Learn More about insider trades at Tarsus Pharmaceuticals.
Information on this page was last updated on 3/20/2025.

Bobak R. Azamian Insider Trading History at Tarsus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/24/2025	Sell	6,000	$50.00	$300,000.00	824,106
3/20/2025	Sell	8,534	$50.11	$427,638.74	53,635
3/18/2025	Sell	7,131	$46.29	$330,093.99	70,720
3/18/2024	Sell	10,415	$30.60	$318,699.00	26,456
12/27/2023	Sell	8,000	$20.22	$161,760.00	830,106
12/20/2023	Sell	40,000	$20.27	$810,800.00	838,106
10/18/2023	Sell	8,000	$13.24	$105,920.00	886,106
9/20/2023	Sell	8,000	$17.21	$137,680.00	894,106
8/23/2023	Sell	8,000	$17.23	$137,840.00	902,106
7/19/2023	Sell	103,900	$20.01	$2,079,039.00	910,106
7/12/2023	Sell	9,000	$17.35	$156,150.00	1,014,006
6/21/2023	Sell	8,000	$18.63	$149,040.00	1,023,006
6/14/2023	Sell	9,000	$18.58	$167,220.00	1,031,006
6/8/2023	Sell	3,100	$20.01	$62,031.00	1,040,006
5/17/2023	Sell	8,000	$15.90	$127,200.00	1,043,106
5/10/2023	Sell	9,000	$16.80	$151,200.00	1,051,106
5/1/2023	Sell	5,841	$15.10	$88,199.10	1,060,106
4/28/2023	Sell	4,278	$15.13	$64,726.14	1,065,947
4/21/2023	Sell	2,311	$15.03	$34,734.33	1,070,225
4/19/2023	Sell	8,000	$13.60	$108,800.00	1,072,536
3/22/2023	Sell	709	$12.64	$8,961.76	9,334
3/20/2023	Sell	741	$12.61	$9,344.01	10,722
3/17/2023	Sell	795	$13.28	$10,557.60	11,463
3/15/2023	Sell	8,000	$13.79	$110,320.00	1,080,536
3/8/2023	Sell	4,853	$15.02	$72,892.06	1,089,253
2/8/2023	Sell	9,000	$15.14	$136,260.00	1,102,106
1/23/2023	Sell	4,856	$15.45	$75,025.20	1,111,106
1/20/2023	Sell	240	$15.00	$3,600.00	1,116,373
1/18/2023	Sell	8,000	$14.56	$116,480.00	1,116,613
1/11/2023	Sell	3,904	$15.11	$58,989.44	1,124,613
1/9/2023	Sell	729	$15.15	$11,044.35	1,129,422
1/6/2023	Sell	411	$15.00	$6,165.00	1,129,740
12/21/2022	Sell	8,000	$14.57	$116,560.00	1,130,151
12/16/2022	Sell	535	$15.01	$8,030.35	1,138,151
12/14/2022	Sell	6,420	$15.08	$96,813.60	1,138,686
10/19/2022	Sell	8,000	$16.92	$135,360.00	1,162,106
10/12/2022	Sell	9,000	$15.91	$143,190.00	1,170,106
9/21/2022	Sell	8,000	$16.31	$130,480.00	1,179,106
9/14/2022	Sell	9,000	$16.01	$144,090.00	1,187,106
8/17/2022	Sell	8,000	$16.59	$132,720.00	1,196,106
10/12/2021	Sell	5,531	$26.30	$145,465.30
10/8/2021	Sell	302	$25.02	$7,556.04
8/11/2021	Sell	1,917	$25.07	$48,059.19	1,750
8/9/2021	Sell	827	$25.02	$20,691.54	1,750
8/5/2021	Sell	1,370	$25.00	$34,250.00

See Full Table

Bobak R. Azamian Buying and Selling Activity at Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Company Overview

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Today's Range

Now: $51.01

$49.53

$51.71

50 Day Range

MA: $48.82

$41.29

$56.94

2 Week Range

Now: $51.01

$20.08

$57.28

Volume

291,655 shs

Average Volume

640,021 shs

Market Capitalization

$1.96 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05